Dear Guests,

The ForTra gGmbH for Research Transfer (subsidiary of the Else Kröner Fresenius Foundation) would like to invite you to the 4th EKFS Translational Research Workshop on September 22 & 23, 2021 in Frankfurt/Main. The official program is attached to the invitation.
At the workshop distinguished experts will discuss the important challenge of increasing the chances of biomedical products reaching the market and benefiting patients.

“How to Improve Translational Medicine”

They will present possible solutions to increase the chances of biomedical products reaching the market and benefiting patients.

Come and join us in Frankfurt to discuss the possibilities for empowering translational medicine and learn about a variety of tools to support and finance your translational research project on its way to clinical application.

Attending the workshop is free of charge, but you need to register in advance at the following email address: translatorik@ekfs.de

The limited seating will be allocated according to the time of registration (first come, first served).

We look forward to welcoming you in September 2021!

Best regards,

Martin Zörnig

A (very) limited number of parking spaces will be available at the PEG Building. Please use public transportation.

Starting from the main train station: go by U4 or U5 to the Willy-Brandt-Platz stop, switch to U1, U2, U3, U8 to the Holzhausenstraße stop, then a 300m walk on Bremer Straße to the Campus.

Bus: Nr. 36 or 75 to Uni Campus Westend or Nr. 75 to Max-Horkheimer-Straße

Bus: Nr. 64 to Bremer Platz and Bremer Straße
Program

4th EKFS Translational Research Workshop

September 22, 2 p.m. & September 23, 9 a.m.

Casino Building of the University of Frankfurt
Renate von Metzler Saal – Campus Westend
Theodor-W.-Adorno-Platz 1
60323 Frankfurt am Main, Germany

Wednesday, 22nd of September, 2021

14:00 Prof. Martin Zörnig (Managing Director, ForTra gGmbH für Forschungstransfer der Else Kröner-Fresenius-Stiftung): Welcome and introduction of the EKFS funding line for translational research

14:30 – 15:30 Keynote Lecture 1
Dr. Kevin Cullen (Vice President of Innovation and Economic Development, King Abdullah University of Science and Technology, Saudi Arabia): For Love or Money? Why Universities do Tech Transfer

15:30 – 16:15 Dr. Matthias Stein-Gerlach (Head of Business Development, Lead Discovery Center GmbH): Introducing the Lead Discovery Center (LDC) – How to turn a biological target hypothesis into a druggable compound

16:15 – 17:15 Dr. Philipp Uhl (Heidelberg University Hospital): LipOra micelle technology for oral peptide drug delivery – Mastering major translational challenges (currently funded EKFS translational research project)

17:15 – 19:30 Refreshments, Get-together

20:00 Speakers Dinner

Thursday, 23rd of September, 2021

Translation Toward Clinical Trial Application
(Chairman: Dr. Ansgar Santel, Technology Development Manager, Ascenion GmbH)

09:00 – 09:45 Dr. Martina Schüßler-Lenz (Paul-Ehrlich-Institute and Chair of EMA Committee for Advanced Therapies): Translation of innovative medicines from bench to bedside
09:45 – 10:30  Dr. Gabriele Dallmann (Biopharma Excellence): Important regulatory aspects to be addressed on the way to first-in-human clinical studies

10:30 – 11:00  Coffee Break

11:00 – 11:45  Prof. Winfried Wels (Georg-Speyer-Haus, Frankfurt): Phase I clinical trial of intracranial injection of CAR-engineered NK cells in patients with recurrent HER2-positive glioblastoma (currently funded EKFS translational research project)

11:45 – 12:30  Prof. Simone Spuler (Charité Universitätsmedizin Berlin and Max-Delbrück-Center for Molecular Medicine): First-in-human clinical trial using primary human muscle stem cells (currently funded EKFS translational research project)

12:30 – 13:30  Lunch

13:30 – 14:15  Keynote Lecture 2
Dr. Kathrin Körner (Merck KGaA): Second medical use patents – trash or treasure? Considerations from 20 years in pharma patenting

Financing Options Following EKFS Funding
(Chairman: Dr. Axel Polack, General Partner Joint Polish Investment Fund)

14:15 – 14:30  Dr. Mathias Schott (FCF Fox Corporate Finance GmbH): Why early-stage biotech financings often fail and what is the role of a corporate finance advisor?

14:30 – 14:45  Dr. Frank Hensel (Principal, High-Tech Gründerfonds): Partnering with the HighTech-Gründerfonds for investments in early drug development

14:45 – 15:00  Dr. Martin Raditsch (Innovectis Gesellschaft für Innovations-Dienstleistungen mbH): Financing Development Projects following EKFS support, the CARMA Project

15:00 – 15:15  Florian Jehle (Fresenius Medical Care Ventures GmbH): Financing Innovations through Corporate Venture Capital

15:15 – 15:30  Barbara Diehl (Chief Partnership Officer, Federal Agency for Disruptive Innovation (SPRIN-D)): Introducing SPRIN-D: Supporting breakthrough innovations

15:30 – 16:00  Panel discussion chaired by Dr. Axel Polack (General Partner Joint Polish Investment Fund): Financing the development of novel therapies – how does it work?

16:00 – 16:20  Coffee Break

16:20 – 17:15  Keynote Lecture 3
Prof. Aled Edwards (University of Toronto, Director of the Structural Genomics Consortium, Director of M4K Pharma): Open drug discovery – a path to affordable medicines for all

17:15  Prof. Martin Zörnig (Managing Director ForTra): Closing remarks